Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy

Shohei Moriyama, Michinari Hieda, Megumi Kisanuki, Shotaro Kawano, Taku Yokoyama, Mitsuhiro Fukata, Hitoshi Kusaba, Toru Maruyama, Eishi Baba, Koichi Akashi, Haruhisa Fukuda

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Background Cancer treatment with vascular endothelial growth factor signalling pathway (VSP) inhibitors frequently causes hypertension. Although previous reports suggested that the antihypertensive drug renin-angiotensin system inhibitor (RASI) may have a positive synergistic effect with VSP inhibitors, the actual impact on clinical outcomes is unknown. Objectives The study aims to clarify whether RASIs exhibit clinical benefits for patients with cancer with hypertension. Method From the Longevity Improvement and Fair Evidence Study database, comprising Japanese claims data between 2016 and 2020, we reviewed 2380 patients treated with VSP inhibitors who received antihypertensive treatment during cancer therapy. The patients were classified into two groups: with-RASI (n=883) and without-RASI (n=1497). In addition, 1803 of these patients treated for hypertension with RASI-only (n=707) or calcium channel blocker-only (n=1096) were also reviewed. The time-to-treatment failure (TTF), the interval from initiation of chemotherapy to its discontinuation, was applied as the primary endpoint. Results The median TTFs were 167 (60-382) days in the with-RASI group and 161 (63-377) days in the without-RASI group (p=0.587). All models, including Cox proportional hazard models and multiple propensity score models, did not reveal the superiority of with-RASI treatment. In the propensity score matching model, the HR for treatment with-RASI compared with that for without-RASI was 0.96 (95% CI 0.86 to 1.06, p=0.386). In addition, the TTFs of RASI-only were not superior to calcium channel blocker-only (p=0.584). Conclusions RASIs for hypertension do not benefit clinical outcomes during cancer therapy with VSP inhibitors. In addition, RASIs and calcium channel blockers have comparable clinical efficacy as first-line antihypertensive.

Original languageEnglish
Article numbere002135
JournalOpen Heart
Volume9
Issue number2
DOIs
Publication statusPublished - Dec 8 2022

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Effect of renin-angiotensin system inhibitors in patients with cancer treated with anti-VEGF therapy'. Together they form a unique fingerprint.

Cite this